What is Zacks Research's Forecast for TBPH Q3 Earnings?

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Investment analysts at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Theravance Biopharma in a research note issued to investors on Monday, October 21st. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will earn ($0.03) per share for the quarter, up from their previous estimate of ($0.09). The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.04) per share. Zacks Research also issued estimates for Theravance Biopharma's FY2025 earnings at ($0.01) EPS, Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.04) EPS and FY2026 earnings at $0.55 EPS.

Other equities research analysts have also issued reports about the stock. StockNews.com lowered shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a report on Saturday, August 10th. Leerink Partnrs downgraded Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 6th. TD Cowen cut their price target on Theravance Biopharma from $10.00 to $9.00 and set a "hold" rating on the stock in a research note on Tuesday, August 6th. HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Theravance Biopharma in a research note on Monday, September 16th. Finally, Leerink Partners downgraded Theravance Biopharma from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $15.00 to $10.00 in a report on Tuesday, August 6th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Theravance Biopharma currently has a consensus rating of "Hold" and a consensus target price of $13.75.

Theravance Biopharma Stock Up 1.6 %

Shares of NASDAQ:TBPH opened at $8.80 on Wednesday. The company has a market capitalization of $430.50 million, a price-to-earnings ratio of -9.57 and a beta of 0.25. The company has a 50 day moving average of $8.20 and a two-hundred day moving average of $8.76. Theravance Biopharma has a 52-week low of $7.44 and a 52-week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.25). The company had revenue of $14.26 million during the quarter, compared to analyst estimates of $15.81 million. Theravance Biopharma had a negative net margin of 73.61% and a negative return on equity of 21.29%. During the same quarter last year, the business posted ($0.28) EPS.

Insiders Place Their Bets

In other Theravance Biopharma news, major shareholder Eli Samaha acquired 999,800 shares of the company's stock in a transaction that occurred on Wednesday, August 7th. The shares were purchased at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the purchase, the insider now directly owns 9,511,150 shares in the company, valued at $74,186,970. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 6.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in TBPH. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Theravance Biopharma by 41.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company's stock valued at $5,005,000 after acquiring an additional 163,951 shares during the period. Marshall Wace LLP raised its holdings in shares of Theravance Biopharma by 83.6% during the second quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company's stock valued at $2,523,000 after buying an additional 135,426 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Theravance Biopharma during the second quarter worth approximately $986,000. Wellington Management Group LLP grew its holdings in Theravance Biopharma by 68.0% in the 4th quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company's stock worth $3,227,000 after buying an additional 116,164 shares in the last quarter. Finally, Bank of Montreal Can increased its position in Theravance Biopharma by 141.0% in the 2nd quarter. Bank of Montreal Can now owns 160,138 shares of the biopharmaceutical company's stock valued at $1,414,000 after acquiring an additional 93,702 shares during the period. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.